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A B S T R A C T
Dehydroepiandrosterone (DHEA) and its ester dehydro-
epiandrosterone sulphate (DHEAS) are produced by the
adrenal glands. These hormones are inactive precursors
that are transformed into active sex steroids in peripheral
target tissues. After a peak in early adulthood, there is a
marked decrease in plasma concentrations throughout
adult life. These hormones are thought to affect mood
and well-being, have neurosteroid effects and may influence
the immune system. Animal experiments suggest that
DHEA has many other effects, including anticancer,
immune-enhancing, neurotropic and general antiageing
effects, but information based on studies in humans is
limited. In female patients with adrenal insufficiency,
treatment with DHEA replacement doses of 20 to 50 mg
results in improvements in mood, quality of life and
libido. These studies usually lasted only a few months, so
the effect of chronic DHEA treatment or its effectiveness
in male patients is not known. Some studies suggest a
favourable effect of pharmacological doses of DHEA in the
treatment of depression. DHEA may have a very limited
effect on cognitive function in elderly people, and some
studies suggest a beneficial immunomodulatory effect of
DHEA in patients with autoimmune diseases, but further
studies are warranted before introducing DHEA for these
indications in clinical practice.
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I N T R O D U C T I O N
Dehydroepiandrosterone (DHEA) and its ester dehydro-
epiandrosterone sulphate (DHEAS) are the main secretory
products of the adrenal zona reticularis, and are known
as ‘adrenal androgens’. DHEA is lipophilic, and can be
converted to DHEAS by activity of the enzyme sulpho-
transferase in the liver and adrenal glands. DHEAS is the
hydrophilic storage form that circulates in the blood,
bound to albumin. DHEAS can be converted into DHEA
by activity of the enzyme sulphatase in peripheral tissues. 
DHEA and DHEAS are inactive androgen precursors that
are transformed into active sex steroids in peripheral target
tissues, e.g. hair follicles, prostate, external genitalia, adi-
pose tissue and the brain. These transformations depend
on the tissue activity of metabolising enzymes and result
in the production of active androgens (androstenedione,
testosterone) and oestrogens (oestradiol and oestrone). In
men, about 50% of androgens are derived from adrenal
precursor steroids. In premenopausal women, about 75%
of oestrogen synthesis occurs in peripheral target cells,
and this is almost 100% in postmenopausal women.1 The
sex steroids that are derived from intracellular conversion
of DHEA have their action mainly within the cells in
which they are produced.
The production of DHEA(S) shows a strong association with
age. Serum concentrations of these androgens are low
during the prepubertal period, and reach a peak in early
adulthood. This is followed by a decline throughout adult
life, at the 7th decade the concentrations are only 10 to 20%
of the earlier individual peak concentrations.2,3 In contrast,
cortisol levels in men and women show a progressive
increase (20% overall) with ageing.4 It has been suggested
that the decrease in cortisol/DHEA ratio may cause a meta-
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bolic shift towards a catabolic state during ageing and may
negatively affect the cognitive function in the elderly.4,5
DHEA crosses the blood-brain barrier and may act in the
brain as a neurosteroid via effects on neurotransmitter
function. A specific nuclear hormone receptor for DHEA
has not been identified, but DHEA may act on the N-
methyl-D-aspartate (NMDA) receptor as a modulator of the
response to NMDA or as an allosteric antagonist at the
level of the -aminobutyric acid (GABA) receptor.6 DHEA
increases neuronal excitability and initiates alterations in
synaptic transmission in the hippocampus. Cognitive
processes may therefore be influenced by DHEA.7
Animal experiments suggest that DHEA has many effects,
including anticancer, immune-enhancing, neurotropic
and general antiageing effects. However, most experiments
with DHEA(S) have been performed in rodents, which
have little circulating DHEA(S). Therefore, as DHEA
physiology in humans is clearly different from that in
nonprimate mammals, these experiments are of limited
significance for humans.8 In the next paragraphs we
focus on studies on the effects of DHEA administration
in various conditions in humans.
D H E A  R E P L A C E M E N T  I N  A D R E N A L
I N S U F F I C I E N C Y
In patients with adrenal insufficiency, health-related
quality of life is impaired despite adequate glucocorticoid
and mineralocorticoid replacement.9 As these patients are
DHEA deplete, several studies have assessed the effects
of DHEA administration in adrenal insufficiency. The
most important are discussed below (see also table 1). 
In a double-blind, placebo-controlled, crossover study, 24
women with primary or secondary adrenal insufficiency
received 50 mg of DHEA or placebo orally, each for four
months. Psychological and sexual functioning were evalu-
ated using several validated questionnaires. Treatment
with DHEA for four months resulted in significant
improvements as compared with placebo. The greatest
improvements occurred in the scores for depression and
anxiety, compatible with a neurosteroidal action of DHEA.
Sexuality improved as well. This was accompanied by an
increase in peripheral androgen synthesis, as serum con-
centrations of DHEA(S), and testosterone returned to the
normal range, while serum concentrations of sex hormone-
binding globulin, and total and high-density cholesterol
decreased. Side effects were transient and mild. The same
authors did not find an effect of DHEA on carbohydrate
metabolism, body composition or serum insulin.10 DHEA
administration did result in a significant increase in
osteocalcin as compared with placebo, suggesting an
osteoanabolic effect of DHEA. There was a nonsignificant
improvement in physical capacity, and sense of well-being
and self-perception improved significantly after four
months of DHEA treatment. 11
In another blinded, crossover study in 39 patients with
Addison’s disease, the effect of an oral daily dose of 50
mg DHEA for 12 weeks was evaluated. This was the only
S E P T E M B E R  2 0 0 5 ,  V O L .  6 3 ,  N O .  8
Bovenberg, et al. Dehydroepiandrosterone administration in humans.
301
Table 1 DHEA therapy in adrenal insufficiency
Study Arlt et al.10 Hunt et al.12 Johannson et al.13 Løväs et al.14
Callies et al.11
Subjects 24 women 24 women, 15 men 38 women 39 women
Age range (years) 23-59 25-69 25-65 18-70
Diagnosis Primary and secondary AI Primary AI Secondary AI Primary and 
secondary AI
Study design 1 1 2 2
Duration of DHEA therapy 9 months 7 months 6 months 9 months
Daily DHEA dose 50 mg 50 mg 30 mg (<45 years) 25 mg 
20 mg (>45 years)
Results
Body composition No change No change No change
Lipids Decrease TC and HDL-C No change No change No change
Bone markers and BMD Increase osteocalcin level BMD no change Osteocalcin level Osteocalcin and 
Osteocalcin level unchanged deoxypyridinoline
unchanged unchanged
Mood/well-being Improvement in scores Self-esteem improved No change No change
for depression and anxiety
Sexuality Improved No change No change No change
1 = double=blind, placebo-controlled, randomised, cross-over; 2 = double-blind, placebo-controlled, parallel; AI = adrenal insufficiency; 
BMD = bone mineral density; DHEA = dehydroepiandrosterone; HDL-C = high-density lipoprotein cholesterol; TC = total cholesterol.
study that also included men. DHEA administration
resulted in significant improvement in some aspects of
psychological functioning, such as self-esteem, and in
improvements in mood and fatigue, especially in the
evening. DHEA had no effect on libido and sexual func-
tion, memory or cognition. Further, no effect on bone
metabolism was found, the authors attributed this to the
short duration of treatment.12
In another study, 38 women with adrenal insufficiency
due to hypopituitarism were treated with oral DHEA for
six months in a randomised, placebo-controlled, double-
blind study, followed by a six-month open treatment period.
The DHEA dose was 30 mg/day when <45 years, and
20 mg/day when >45 years. The primary goal was to
study the effect on quality of life, well-being and behaviour.
Treatment with DHEA did not result in a change in
general well-being as compared with baseline, but the
partner questionnaire did reveal an overall improvement
in the DHEA-treated group. Compared with placebo,
DHEA treatment did not influence sexual interest and
activity, whereas during the open phase most women
reported an increase. No changes in glucose metabolism,
lipoproteins, IGF-1, coagulation parameters, body compo-
sition or bone metabolism were observed.13
Løvås et al. treated 39 women with adrenal insufficiency
with either placebo or DHEA, 25 mg/day for nine
months.14 In the DHEA group the levels of DHEAS,
androstenedione and testosterone significantly increased
as compared with baseline. Health status or sexuality did
not improve in the DHEA group as compared with the
placebo group. Several side effects, including sweating,
hirsutism, acne and itching occurred more often in the
DHEA group than in the placebo group.
To define a suitable replacement dose, nine patients with
Addison’s disease were randomised to oral DHEA 50 mg
(n=5) or 200 mg (n=4) daily for three months. Oral doses
of 50 mg/day increased circulating levels of DHEA from
subnormal to the upper part of the reference range for
young individuals, the 200 mg dose resulted in supra-
physiological levels, suggesting that 50 mg/day is a
replacement dose, and 200 mg/day a pharmacological
dose. Five of the nine participants experienced a marked
increase in psychological and general well-being.
However, from the report it cannot be derived which
dosage these five participants used.15
In conclusion, trials on DHEA replacement in patients
with adrenal insufficiency have mainly been performed in
female patients and usually lasted only a few months.
Improvements in mood, health-related quality of life and
libido were seen in some but not all studies and only if
DHEA doses of 50 mg were administered. No convincing
effects on bone density, body composition or serum lipid
levels were found, and no long-term studies have been
carried out to assess the possible effect of DHEA in either
replacement or pharmacological dose on the incidence of
cancer or cardiovascular disease.
E F F E C T  O F  D H E A  R E P L A C E M E N T  O N
M O O D ,  W E L L - B E I N G  A N D  C O G N I T I O N
Ageing results in a decline in concentrations of DHEA,
which may have physiological significance.4 Morales et al.
demonstrated an improvement in self-reported physical
and psychological well-being in middle-aged and elderly
men and women after administration of a daily dose of
50 mg DHEA for three months.16 The same group also
did a study on the effects of a DHEA 100 mg/day, but in
this report the effect of this higher DHEA dose on well-
being was not mentioned.17 In a double-blind cross-over
study, 22 healthy male volunteers received four months of
DHEA (50 mg/day) and four months placebo treatment.
In these healthy men with age-related physiological
decline of DHEA secretion, no obvious benefit of DHEA
replacement was found.18 Wolkowitz et al. randomised 22
subjects with a major depression to receive either DHEA
(30-90 mg/day) or placebo for six weeks.19 They concluded
that patients treated with DHEA showed a greater anti-
depressant response (an overall enhancement of mood
scores by 30.5%) than those who were treated with placebo.
In a recently published study, six weeks of DHEA therapy
in a pharmacological dose (90 mg/day for three weeks
and 450 mg/day for three weeks), was compared with
placebo for six weeks in men (n=23) and women (n=23)
aged 45 to 65 years with midlife-onset major or minor
depression. DHEA administration in a pharmacological
dose was associated with a significant improvement
compared with both baseline (p<0.01) and placebo treat-
ment (p<0.01).20
The mechanism of the possible antidepressant effect of
DHEA is unclear. DHEA crosses the blood-brain barrier
and may interact directly with brain function by affecting
serotonin and/or GABA receptors. Secondly, in brain
cells DHEA is a precursor for testosterone and oestrogen
formation, and increases in the levels of these hormones
can enhance mood. Another theory suggests that a normal
DHEA/cortisol ratio is required for a good balance
between anabolic and catabolic steroid effects. Cortisol
levels are increased in major depression, so DHEA
administration may restore this ratio.21
D H E A  A D M I N I S T R A T I O N  T O  I M P R O V E
C O G N I T I V E  F U N C T I O N  I N  E L D E R L Y
P E O P L E
Serum levels of DHEA(S) decrease during ageing, resulting
in a progressive decrease in the serum DHEA(S)/cortisol
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ratio. It has been hypothesised that this may impair cog-
nitive function. DHEA administration may restore the
DHEA(S)/cortisol ratio, thus potentially improving cogni-
tive function and preventing neurotoxic effects of cortisol.
This hypothesis resulted in four placebo-controlled clinical
trials that investigated the effect of DHEA administration
on cognitive function in elderly people. These studies
were reviewed by Huppert et al.22 All four studies used a
daily oral DHEA dose of 50 mg, for periods lasting less
than three months. Few significant changes were found.
In one study DHEA improved immediate and delayed
recall in a visual memory test compared with placebo,
while no improvement in a verbal memory test, nor in
four other cognitive tests was seen.23 Another study found
a deterioration in a test following a psychological stressor
in the placebo group, which was not seen in the DHEA
group.24 The other studies did not demonstrate any
beneficial effects of DHEA administration.25,26 The overall
conclusion of Huppert et al. was that there is very limited
evidence for a beneficial effect of a daily oral dose of 50 mg
DHEA on cognitive function in elderly people.22 Using a
higher dose of 100 mg DHEA a day for three months,
Flynn et al. did not find clinically meaningful changes in
39 healthy elderly men either.27
D H E A  A D M I N I S T R A T I O N  I N  
P O S T M E N O P A U S A L  W O M E N
In women the synthesis of DHEA occurs mainly in the
adrenal cortex and DHEA serves as the main precursor of
active oestrogens in postmenopausal women. The reduction
in DHEA(S) formation by the adrenals during ageing
results in a reduction in the formation of androgens and
oestrogens in peripheral tissues. It has been suggested
that this could influence well-being and the occurrence of
osteoporosis, obesity and insulin resistance in post-
menopausal women. In the last few years several trials
have assessed whether administration of DHEA would
improve interest in sex, sexual satisfaction, quality of life
or osteoporosis in postmenopausal women. Barnhart et al.
found no difference in improvements in mood, libido,
cognition, memory or well-being after treatment with
DHEA (50 mg/day for three months) vs placebo in 60
perimenopausal women.25 Genazzani et al. studied the
effect of oral administration of 25 mg DHEA daily in 20
postmenopausal women in a 12-month prospective study
that was not blinded or randomised.28 They found an
increase in the circulating levels of all DHEA-derived
steroids, osteocalcin, as well as growth hormone and IGF-1
during DHEA supplementation. An improvement in psy-
chological functioning was also found. These authors
concluded that DHEA administration may be considered
in postmenopausal women.
D H E A  A D M I N I S T R A T I O N  I N  P A T I E N T S
W I T H  A U T O I M M U N E  D I S E A S E S
Because of its immunomodulatory effects in animal
studies, DHEA administration has been studied as a
potential pharmacological tool in the treatment of human
autoimmune diseases. In 21 patients with severe systemic
lupus erythematosus (SLE), DHEA administration 
(200 mg/day vs placebo for six months) was added to
conventional treatment. DHEA administration had a
beneficial effect on lupus outcomes and protected against
steroid-induced osteopenia.29 This effect on bone density
could not be confirmed by Hartkamp et al.30 Chang et al.
investigated 120 adult women with active lupus, who
were treated with DHEA, 200 mg/day or placebo, for 24
weeks.31 They found a reduction in disease flares and the
patients perceived a decrease in disease activity. Side
effects (acne, hirsutism) were mild.
C O N C L U S I O N
DHEA is an adrenal androgen for which many effects in
different clinical situations have been postulated. Many
studies have been performed to assess the importance of
DHEA administration. In most studies in patients with
adrenal insufficiency, oral DHEA replacement is bio-
chemically effective, well tolerated and associated with
some improvement in well-being, mood and fatigue.
This may at least partly be mediated by neurosteroid
effects of DHEA. However, all studies have been small
and short term, and studies in adrenal insufficiency have
mainly been carried out in women. So far no studies have
compared the effects of DHEA administration with those
of other anabolic steroid hormones in patients with adrenal
insufficiency. Side effects of treatment with DHEA were
mild and androgen related.
Some studies suggest a favourable effect of DHEA in
pharmacological doses in treatment of depression. So far,
no consistent beneficial effect of DHEA administration
on mood, general well-being and on cognitive function in
elderly people has been found. DHEA administration in
postmenopausal women needs to be assessed in larger
and longer-lasting studies before therapy with DHEA is
used for these purposes. Pharmacological therapy with
DHEA in autoimmune diseases, such as SLE, may prove
to be beneficial for these patients. More and longer-term
studies are required to demonstrate the immunomodula-
tory effects of DHEA administration in patients with SLE. 
Further, long-term studies would also need to assess if
long-term treatment with DHEA in either pharmacological
or physiological doses will have any effect on the incidence
of cardiovascular or malignant disease.
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